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http://dx.doi.org/10.1016/j.kjms.201Abstract Ankle-brachial index (ABI) and brachial-ankle pulse wave velocity (baPWV) are
markers for peripheral artery occlusive disease (PAOD) and arterial stiffness, respectively.
The aims of this study were to assess whether PAOD and arterial stiffness progressed and to
determine the risk factors for ABI and baPWV progression in patients on hemodialysis. This
study enrolled 173 routine patients on hemodialysis. Both ABI and baPWV were measured by
an ABI-form device at baseline and at 1 year of follow-up. Progression in ABI was defined as
reduction in ABI exceeding 0.3, while baPWV measured at 1 year of follow-up exceeding that
at baseline indicated baPWV progression. Comparison with baseline data showed increase in
both prevalence of ABI < 0.9 (p Z 0.045) and baPWV (p Z 0.028) at 1 year of follow-up.
Multiple linear regression analyses identified high fasting glucose and old age as independent
factors of annual change in ABI and baPWV, respectively. Good control of blood sugar may
contribute to delay the progression of peripheral artery disease in patients on hemodialysis.
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A high prevalence of peripheral artery occlusive disease
(PAOD) and increased artery stiffness have been reported in
the end-stage renal disease (ESRD) population and are
associated with increased morbidity and mortality [1e4].
There is growing evidence that uremia may predispose
sufferers to PAOD progression and increased arterial stiff-
ness with multiple pathogenic mechanisms involved,
including deranged calcium/phosphate balance, secondary
hyperparathyroidism, homocysteine, lipoprotein(a)
metabolism, fluid overload, alterations in the angiotensin
and endothelin systems, malnutrition, uremic toxins,
oxidative stress, insulin resistance, and alterations in
inflammatory and coagulation pathways [4,5].
A clinical device has been developed to automatically
and simultaneously record the pulse waves of the
brachial and posterior tibial arteries, using an automated
oscillometric method. Using this device, we can easily
and automatically calculate the ankle-brachial index
(ABI) and brachial-ankle pulse wave velocity (baPWV)
[6,7]. ABI has been reported to be a good marker for
atherosclerosis and an ABI of <0.9 was useful in the
diagnosis of PAOD [8e10], while baPWV has been taken as
a good marker for arterial stiffness [11,12]. Previous
cross-sectional studies have identified the risk factors of
PAOD and increased artery stiffness in advanced chronic
kidney disease and patients on hemodialysis, including
old age, hypertension, diabetes mellitus (DM), previous
coronary artery disease, previous cerebrovascular
disease, wider pulse pressure, hyperlipidemia, malnu-
trition, and smoking [4,13,14]. However, there have been
few studies evaluating the progression of PAOD and
arterial stiffness longitudinally, or determining the risk
factors of ABI and baPWV progression in patients on
hemodialysis in Taiwan, an area with the highest preva-
lence of ESRD [15]. The aims of the present study were to
assess the progression in PAOD and arterial stiffness and
to determine the risk factors for ABI and baPWV
progression in patients on hemodialysis.
Methods
Study design and participants
This is a prospective and observational study conducted at
a single dialysis clinic in a regional hospital in Taiwan. All
routine patients on hemodialysis in this hospital were
included, except two patients who refused to be examined
by an ABI-form device, four patients with atrial fibrilla-
tion, and six patients with both legs amputated due to
complications of DM. Initially, 196 patients (91 men and
105 women) were included in this study. The ABI was
measured twice within 1 year. During the follow-up
period, 11 deaths were recorded in these 196 patients
(5.6%), 10 patients were transferred to other hospitals,
and two patients refused further examinations. Finally,
173 patients (80 men and 93 women) completed the study.
The protocol was approved by our Institutional Review
Board and all enrolled patients gave written, informed
consent.Hemodialysis
All patients underwent routine hemodialysis three times
a week using a Toray 321 machine (Toray Medical Company,
Tokyo, Japan). Each hemodialysis session lasting 3e4 hours
was performed using a dialyzer with a blood flow rate of 250-
300 mL/minute and a dialysate flow rate of 500 mL/minute.
Assessment of ABI and baPWV
Both ABI and baPWV might be influenced by hemodialysis
[16]; hence, all measurements were made 10e30 minutes
before hemodialysis. The measurements were taken using
an ABI-form device (VP1000; Colin Co. Ltd., Komaki, Japan)
[6,7,17] in a room with a temperature of around 25C
following a 5-minute rest upon arrival at the clinic. Occlu-
sion and monitoring cuffs were placed tightly around the
upper arms without blood access and with both sides of the
lower extremities in the supine position. Dividing the ankle
systolic blood pressure by the arm systolic blood pressure
gave the ABI and the lower value of the ankle systolic blood
pressure was used in the calculation. For measuring baPWV,
pulse waves obtained from the brachial and tibial arteries
were recorded simultaneously, and the transmission time,
defined as the time interval between the initial increase in
brachial and tibial waveforms, was determined. The
transmission distance from the arm to each ankle was
calculated according to body height. The baPWV value was
automatically computed as the transmission distance
divided by the transmission time. After obtaining bilateral
baPWV values, the highest one was taken as the represen-
tative value for each participant. Both ABI and baPWV
measurements were made at baseline and at the 1 year of
follow-up. The automatic device and its reproducibility
have been validated in previous research [17].
Collection of demographic, medical, and laboratory
data
Demographic and medical data including age, sex, smoking
history, and comorbidities were obtained from medical
records and interviews with patients. Body mass index (BMI)
was calculated as the ratio of weight in kilograms divided by
the square of height in meters. Laboratory data were ob-
tained from fasting blood samples using an autoanalyzer
(Roche Diagnostics GmbH, D-68298 COBAS Integra 400,
Mannheim, Germany). High-sensitivity C-reactive protein
(Dade BehringMarburgGmbH,Germany)wasmeasured using
commercially available kits. Serum intact parathyroid
hormone concentration was evaluated using a commercially
available two-sided immunoradiometric assay (CIS Bio
International, Gif Sur Yvette, France). Blood samples were
centrifuged within 1 hour of collection and frozen at 20C
until analysis. Plasma homocysteine levels were determined
by fluorescence polarization immunoassay using an IMx
Homocysteine kit (Abbott Laboratories, Abbott Park, IL,
USA). Blood samples were obtained within 1 month of
enrollment. In addition, information regarding patient
medications including aspirin, angiotensin converting
enzyme inhibitors, angiotensin II receptor blockers, b-
blocker, calcium channel blocker, and HMG-CoA reductase
84 S.-R. Hsu et al.inhibitors (statins) during the study periodwas obtained from
medical records.
Definitions of progression of ABI and baPWV
OABI was defined as ABI measured at 1-year follow-up
minus ABI measured at baseline. Reduction in ABI
exceeding 0.3 was considered as progression of ABI [18].
ObaPWV was defined as baPWV measured at 1-year follow-
up minus baPWV measured at baseline. A positiveObaPWV
indicated progression of baPWV.
Statistical analysis
Statistical analysis was performed using SPSS 12.0 for
windows (SPSS Inc., Chicago, IL, USA). Data are expressedTable 1 Baseline characteristics of the study patients.
Characteristics Study patients (n Z 173)
Age (yr) 57.3  12.7
Male sex (%) 46.2
Smoking history (%) 24.9
Diabetes mellitus (%) 39.3
Hypertension (%) 70.5
Coronary artery disease (%) 24.3
Cerebrovascular disease (%) 9.2
Duration of hemodialysis (mo) 72.4  53.4
Systolic blood pressure (mmHg) 148.8  24.6
Diastolic blood pressure (mmHg) 80.4  14.5
Pulse pressure (mmHg) 68.7  16.9
Heart rate (beats/min) 82.1  13.9
Body mass index (kg/m2) 24.3  3.7
ABI < 0.9 (%) 23.1
baPWV (cm/s) 1795.0  458.5
Laboratory parameters
Albumin (g/dL) 3.97  0.25
Fasting glucose (mg/dL) 119.5  57.9
Triglyceride (mg/dL) 152.9  98.4
Total cholesterol (mg/dL) 180.1  40.7
HDL-cholesterol (mg/dL) 41.1  10.7
LDL-cholesterol (mg/dL) 90.6  28.3
Hematocrit (%) 30.5  3.7
Calcium-phosphorous product 47.1  10.7
Uric acid (mg/dL) 7.7  1.5
PTH (pg/mL) 425.6  329.8
hsCRP (mg/L) 0.70  1.00
Homocysteine (mmol/L) 29.4  9.9
Cardio-thoracic ratio > 50% 36.4
Medications
Aspirin use (%) 17.9
ACEI and/or ARB use (%) 26.0
b-blocker use (%) 16.8
Calcium channel blocker use (%) 35.3
Statins use (%) 32.9
ABI Z ankle-brachial index; ACEI Z angiotensin converting
enzyme inhibitor; ARB Z angiotensin II receptor blocker;
baPWV Z brachial-ankle pulse wave velocity; HDL Z high-
density lipoprotein; hsCRP Z high-sensitivity C-reactive
protein; LDL Z low-density lipoprotein; PTH Z parathyroid
hormone.as numbers and percentages, or mean  standard devia-
tion. The differences between groups were analyzed by
Chi-square test for categorical variables or by independent
t-test for continuous variables. Paired t-test was performed
to compare the prevalence of ABI < 0.9 and baPWV values
at baseline and 1-year follow-up. Linear regression analysis
was employed to identify the factors associated with the
ratio of OABI to baseline ABI and ObaPWV to baseline
baPWV. Age, sex, and the independent variables with
a p < 0.2 in the univariate analysis were selected in the
multivariate analysis. A p value of less than 0.05 indicated
significant difference.Results
The clinical characteristics of the study patients are shown
in Table 1. The mean age of the 173 patients was
57.3  12.7 years and there were 80 men and 93 women.
Among our patients, 39.3% were diabetic and 70.5%
received medications for high blood pressure. Pre-existing
and documented coronary arterial and cerebrovascular
diseases were noted in 24.3% and 9.2% of patients,
respectively. Biochemical data were listed in the Table 1.
At baseline, the prevalence of ABI < 0.9 was 23.1% and the
average baPWV was 1795.0  458.5 cm/s. The underlying
etiologies of hemodialysis in our study patients includedFigure 1. (A) The prevalence of ABI < 0.9 increased yearly
during 1-year follow-up (23.1%, and 30.1%; p Z 0.045); (B)
values of baPWV increased yearly during 1-year follow-up
(1795.0  458.5, and 1880.7  604.0; p Z 0.028).
ABI Z ankle-brachial index; baPWV Z brachial-ankle pulse
wave velocity.
Table 2 Comparison of baseline characteristics between progressors and non-progressors of ABI.
Parameters Progressors of ABI
(n Z 10)
Non-progressors of ABI
(n Z 163)
p
Age (yr) 59.5  10.2 57.1  12.9 0.567
Male sex (%) 50.0 46.0 0.806
Smoking history (%) 30.0 24.5 0.711
Diabetes mellitus (%) 60.0 38.0 0.194
Hypertension (%) 70.0 70.6 > 0.99
Coronary artery disease (%) 30.0 23.9 0.707
Cerebrovascular disease (%) 10.0 9.2 > 0.99
Duration of hemodialysis (mo) 71.0  65.2 72.4  52.8 0.933
Systolic blood pressure (mmHg) 147.8  18.3 148.9  25.0 0.891
Diastolic blood pressure (mmHg) 75.0  11.4 80.7  14.6 0.226
Pulse pressure (mmHg) 72.8  19.0 68.4  16.8 0.426
Heart rate (beats/min) 82.2  8.1 82.1  14.2 0.984
Body mass index (kg/m2) 23.9  4.0 24.3  3.7 0.716
baPWV (cm/s) 1813.3  498.0 1793.8  457.6 0.897
Laboratory parameters
Albumin (g/dL) 3.81  0.22 4.00  0.28 0.042
Fasting glucose (mg/dL) 156.6  55.7 120.8  62.5 0.079
Triglyceride (mg/dL) 161.3  92.5 154.3  103.1 0.833
Total cholesterol (mg/dL) 178.9  40.2 177.9  40.2 0.936
HDL-cholesterol (mg/dL) 40.6  7.7 41.1  10.9 0.897
LDL-cholesterol (mg/dL) 89.9  24.8 90.7  28.6 0.933
Creatinine (mg/dL) 10.1  2.4 10.3  2.3 0.690
Hematocrit (%) 31.7  3.9 31.0  3.8 0.547
Calcium-phosphorous product 41.9  6.4 46.2  12.8 0.300
Uric acid (mg/dL) 7.6  1.3 7.7  1.6 0.838
PTH (pg/mL) 531.4  379.9 418.7  360.9 0.341
hsCRP (mg/L) 0.55  0.46 0.71  1.01 0.667
Homocysteine (mmol/L) 33.9  8.9 29.2  9.9 0.189
Cardio-thoracic ratio > 50% 40.0 36.2 > 0.99
Medications
Aspirin use (%) 30.0 17.2 0.388
ACEI and/or ARB use (%) 20.0 26.4 > 0.99
b-blocker use (%) 20.0 16.6 0.675
Calcium channel blocker use (%) 20.0 36.2 0.497
Statins use (%) 60.0 31.3 0.083
ABIZ ankle-brachial index; ACEIZ angiotensin converting enzyme inhibitor; ARBZ angiotensin II receptor blocker; baPWVZ brachial-
ankle pulse wave velocity; HDLZ high-density lipoprotein; hsCRPZ high-sensitivity C-reactive protein; LDLZ low-density lipoprotein;
PTH Z parathyroid hormone.
ABI and baPWV progression in hemodialysis 85nondiabetic glomerular diseases (42.2%), diabetic kidney
disease (35.3%), hypertension (11.6%), tubulointerstitial
diseases (8.7%), and other diseases (2.3%).
The incidence of de novo ABI < 0.9 is 18.0%. Fig. 1A
shows increasing prevalence of ABI < 0.9 among the
participants during the 1-year follow-up (23.1%, and 30.1%;
p Z 0.045); while Fig. 1B illustrates increasing baPWV in
the same period (1795.0  458.5, and 1880.7  604.0;
p Z 0.028).
The comparison of baseline characteristics between
study patients with and without ABI progression is shown in
Table 2. As can be seen, patients with ABI progression were
significantly associated with lower serum albumin levels
than those without. Multiple linear regression analysis
revealed that covariates in the model included age, sex,
a history of DM, serum albumin level, fasting glucose,homocysteine level, and use of statins. In addition, the
ratio of OABI to baseline ABI were significantly and nega-
tively associated with fasting glucose (b Z e0.222,
p Z 0.018).
Table 3 shows the comparison of baseline characteris-
tics between study patients with and without baPWV
progression. As can be seen, patients with baPWV
progression were significantly associated with a higher
serum creatinine level than those without. Multiple linear
regression analysis revealed that covariates in the model
included age, sex, a history of coronary artery disease,
serum triglyceride level, high-density lipoprotein choles-
terol, creatinine level, and cardiothoracic ratio > 50%. In
addition, the ratio of ObaPWV to baseline baPWV was
independently correlated with age (b Z 0.192,
p Z 0.045).
Table 3 Comparison of baseline characteristics between progressors and non-progressors of baPWV.
Parameters Progressors of
baPWV (n Z 90)
Non-progressors of
baPWV (n Z 83)
P
Age (yr) 56.4  12.8 58.2  12.7 0.360
Male sex (%) 46.7 45.8 0.907
Smoking history (%) 26.7 22.9 0.566
Diabetes mellitus (%) 40.0 38.6 0.846
Hypertension (%) 71.1 69.9 0.859
Coronary artery disease (%) 18.8 30.1 0.085
Cerebrovascular disease (%) 6.7 12.0 0.222
Duration of hemodialysis (mo) 68.6  46.4 76.4  60.1 0.338
Systolic blood pressure (mmHg) 149.2  27.1 148.5  21.8 0.841
Diastolic blood pressure (mmHg) 80.7  15.0 80.0  13.9 0.762
Pulse pressure (mmHg) 68.9  19.1 68.4  14.3 0.850
Heart rate (beats/min) 82.4  15.4 81.8  12.2 0.781
Body mass index (kg/m2) 24.3  3.6 24.2  3.9 0.905
ABI < 0.9 23.3 22.9 0.945
Laboratory parameters
Albumin (g/dL) 3.98  0.26 3.95  0.24 0.496
Fasting glucose (mg/dL) 122.5  60.6 116.2  55.0 0.475
Triglyceride (mg/dL) 139.9  77.4 166.9  115.9 0.071
Total cholesterol (mg/dL) 178.8  39.1 181.4  42.5 0.674
HDL-cholesterol (mg/dL) 42.3  11.1 39.7  10.3 0.122
LDL-cholesterol (mg/dL) 90.9  29.5 90.4  27.1 0.908
Creatinine (mg/dL) 10.6  2.4 9.9  2.2 0.047
Hematocrit (%) 30.6  4.0 30.4  3.2 0.800
Calcium-phosphorous product 46.1  10.2 48.2  13.1 0.248
Uric acid (mg/dL) 7.8  1.6 7.6  1.4 0.410
PTH (pg/mL) 406.3  309.9 446.6  350.8 0.423
hsCRP (mg/L) 0.62  0.85 0.78  1.12 0.299
Homocysteine (mmol/L) 30.1  10.5 28.7  9.2 0.375
Cardio-thoracic ratio >50% 30.0 43.4 0.068
Medications
Aspirin use (%) 18.9 16.9 0.729
ACEI and/or ARB use (%) 28.9 22.9 0.369
b-blocker use (%) 14.4 19.3 0.395
Calcium channel blocker use (%) 36.7 33.7 0.687
Statins use (%) 34.4 31.3 0.663
ABIZ ankle-brachial index; ACEIZ angiotensin converting enzyme inhibitor; ARBZ angiotensin II receptor blocker; baPWVZ brachial-
ankle pulse wave velocity; HDLZ high-density lipoprotein; hsCRPZ high-sensitivity C-reactive protein; LDLZ low-density lipoprotein;
PTH Z parathyroid hormone.
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The present longitudinal study evaluated the progression of
PAOD and arterial stiffness and the influence of athero-
sclerotic risk factors on ABI and baPWV progression in
patients with hemodialysis. We found increase in both
prevalence of ABI < 0.9 and baPWV during 1 year of follow-
up. High fasting glucose and old age were identified as
major factors responsible for the accelerated progression in
ABI and baPWV, respectively.
We have reported the associated risk factors for
abnormal ABI and baPWV in chronic kidney disease and
patients on hemodialysis [13,14]. However, the reported
results were from cross-sectional studies. There are some
recent longitudinal studies examining the risk factors for
PAOD and artery stiffness progression [19e21]. Ohnishi
et al. [20] evaluated longitudinally the risk factors of denovo PAOD in 468 adult elderly men for 5 years. They found
that older age, smoking, cerebrovascular disease, and
coronary artery disease were the risk factors for PAOD. In
our study, we examined the annual change in ABI, not de
novo PAOD, and found that high fasting glucose was asso-
ciated with accelerated progression of ABI. Uremia may
worsen metabolic syndrome features including insulin
resistance, glucose intolerance, and hyperglycemia,
resulting in high cardiovascular morbidity and mortality
[22]. Takenaka et al. [21] studied the associated factors of
annual change in heart-tibial PWV in 72 patients on hemo-
dialysis, and found that higher triglyceride levels and longer
duration of dialysis were associated with greater increase in
heart-tibial PWV. Jung et al. [19] also examined the factors
associated with changes in heart-femoral PWV over one
year in 67 peritoneal dialysis patients, and identified
change in mean arterial pressure and triglyceride as risk
ABI and baPWV progression in hemodialysis 87factors for heart-femoral PWV progression. In their studies,
serum triglyceride levels were evaluated monthly or every
3 months during the observation period, and those
measurements were averaged for analysis. In our study,
only a single measurement of triglyceride level was made,
which might explain the discrepancy between our results
and those obtained by Takenaka and Jung [19,21]. Shino-
hara et al. [5] compared the aortic pulse wave velocity
(PWV) of 71 uremic patients before initiation of hemodial-
ysis with that of 144 patients on chronic hemodialysis, and
found that the predialysis patients had greater aortic PWV
than the patients on hemodialysis. They attributed their
findings to good volume control and reversed insulin resis-
tance in patients with hemodialysis, which might have
favorable effects on arterial stiffness. The same reason
may account for the lack of correlation between the
duration of dialysis and arterial stiffness progression in our
study patients.
In summary, the present study demonstrated increase in
both prevalence of ABI < 0.9 and baPWV during 1 year of
follow-up in patients on hemodialysis. High fasting glucose
and old age were independent determinants of accelerated
progression in ABI and baPWV, respectively. Good control of
blood sugar may help delay the progression of peripheral
artery disease in patients on hemodialysis.References
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